Anavex Life Sciences Corp.
NASDAQ:AVXLBiotechnology
-$0.04 today
- Market cap
- $66.69M
- Beta
- 1.12
- P/E (TTM)
- -5.9
- EPS (TTM)
- -$0.45
Volume 1.06M
Average 1.39M
AVXL Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Anavex Life Sciences Corp.NASDAQ: AVXL
Depreciation & Amortization · Q1 FY2026 · quarter ended Dec 2025
Depreciation & amortization remains negative
Q1 FY2026 depreciation & amortization was $0, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $0.
Context
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 0 | — |
| FY2024 | 2024-09-30 | 0 | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
| FY2021 | 2021-09-30 | 0 | — |
Depreciation & Amortization vs competitors
How AVXL compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.52M USD | -3.0% | +6.5% | 17.7% | |
| LTM Mar 2026 | $12.82M USD | +2.6% | +13.6% | 16.1% | |
| LTM Mar 2026 | $11.4M USD | -12.6% | -3.4% | 620.8% | |
| LTM Mar 2026 | €6.46M EUR | -64.9% | +1.1% | 4.1% | |
| LTM Mar 2026 | $4.5M USD | -21.1% | -14.1% | 5.0% | |
| LTM Mar 2026 | $3.08M USD | +50.1% | +151.3% | — | |
| LTM Sep 2026 | $2.89M USD | -9.4% | +5.6% | — | |
| LTM Mar 2026 | $1.24M USD | -26.3% | -17.4% | 3.5% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $343K USD | +39.4% | +64.2% | — |
| LTM Dec 2025 | $0 USD | — | — | — | |
| Peer median (excluding AVXL) | — | -9.4% | +5.6% | 10.6% | |
Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.98M | 37.92M | 43.72M | 41.84M | 37.59M |
| Selling, General & Admin | 9.02M | 13.07M | 12.05M | 11.04M | 13.82M |
| Operating Expenses | 42M | 50.99M | 55.76M | 52.88M | 51.41M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (37.64M) | (47.62M) | (46.54M) | (43M) | (46.38M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (42M) | (50.99M) | (55.76M) | (52.88M) | (51.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 26K | 947K | 6.52M | 7.32M | 4.68M |
| Interest Expense | 0 | 0 | 964K | 0 | 0 |
| Other Income / Expenses | 4.36M | 3.37M | 8.26M | 9.88M | 5.03M |
| Income Before Tax | (37.64M) | (47.62M) | (47.51M) | (43M) | (46.38M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 268K | 358K | 0 | 0 | 0 |
| Net Income | (37.91M) | (47.98M) | (47.51M) | (43M) | (46.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.54) | (0.62) | (0.60) | (0.52) | (0.54) |
| EPS (Diluted) | (0.54) | (0.62) | (0.60) | (0.52) | (0.54) |
| Weighted Avg Shares | 69.8M | 76.91M | 79.79M | 83.47M | 85.29M |
| Weighted Avg Shares (Diluted) | 69.8M | 76.91M | 79.79M | 83.47M | 85.29M |
Anavex Life Sciences Corp.
NASDAQ:AVXL
Intrinsic Alpha fair value
Locked
Current Price
$0.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.